Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-10-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于2025年度开展外汇套期保值业务的可行性分析报告
Regulatory Filings Classification · 95% confidence The document is a detailed report from Shenzhen BGI Genomics Co., Ltd. regarding the feasibility analysis of conducting foreign exchange hedging business in 2025. It discusses the background, necessity, risk analysis, risk control measures, accounting treatment, and concludes on the feasibility of the hedging business. The content is focused on financial risk management and operational strategy rather than a financial statement or earnings announcement. It is not an announcement of a report publication but a substantive analysis document. The document does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is a specialized report on a financial risk management activity, which aligns best with Regulatory Filings (RNS) as it is a compliance and operational disclosure related to financial risk management and hedging activities, without being a formal financial statement or earnings report.
2024-10-25 Chinese
关于增加与关联方合作建设关联交易额度的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding an increase in the transaction amount for a related-party cooperation construction project. It includes extensive information about the related parties, financial data, project details, reasons for the increase, pricing policies, risk disclosures, and approvals from the board, independent directors, and supervisory board. The document is an official announcement about a related-party transaction increase, not a financial report, earnings release, or management discussion. It does not contain comprehensive financial statements or quarterly results but focuses on corporate governance and transaction disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-10-25 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司2024 年第三季度报告" which translates to "Shenzhen BGI Genomics Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and explanations of financial performance for the third quarter of 2024. The document includes comprehensive financial metrics, shareholder information, and management commentary on business segments and performance. It explicitly states it is a quarterly report and includes actual financial statements and substantive financial data. The length of the document (15,000 characters) and the detailed financial content confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-25 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the convening and decisions made during the fourth Supervisory Board's third meeting, including approval of the 2024 Q3 report, project funding adjustments, related party transaction limits, foreign exchange hedging business, amendments to supervisory meeting rules, and dividend planning. The document is an official announcement of meeting resolutions and approvals, not the full quarterly report or financial statements themselves. It is relatively short (2797 characters) and includes voting results and procedural compliance statements. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement of supervisory board meeting resolutions rather than a full financial report or other specific filing type.
2024-10-25 Chinese
关于变更公司注册资本、修订《公司章程》及部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding changes to the company's registered capital, amendments to the Articles of Association, and revisions to several governance-related rules and systems. It includes extensive legal and procedural details about corporate governance, shareholder rights, board and supervisory meetings, and voting procedures. The content focuses on corporate governance structure and regulatory compliance rather than financial results or audit opinions. There is no indication that this is an annual report, earnings release, or audit report. The document is not a simple announcement of voting results or a proxy solicitation but rather a comprehensive governance-related disclosure. Therefore, the document best fits the category of Governance Information (CGR). The document length and detail also support this classification with high confidence.
2024-10-25 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fourth board of directors of Shenzhen BGI Genomics Co., Ltd. It includes information about the board meeting procedures, voting results, and approvals of various company matters such as the 2024 third quarter report, capital changes, amendments to company bylaws, and plans for a shareholders meeting. The document does not contain the actual financial statements or detailed financial data of the third quarter report but rather the board's approval of it and other governance matters. It is a formal announcement of board decisions and meeting outcomes, not the report itself. Therefore, it fits best into the category of Board/Management Information (MANG). The document length is 4099 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full financial report.
2024-10-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.